---
title: "Biogen trims Apellis pipeline and R&D team after $5.6bn takeover"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291151010.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-06-29T10:42:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291151010.md)
  - [en](https://longbridge.com/en/news/291151010.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291151010.md)
generator: "portal-rs"
---

# Biogen trims Apellis pipeline and R&D team after $5.6bn takeover

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [APLS.US](https://longbridge.com/en/quote/APLS.US.md)

## Related News & Research

- [Amundi Purchases 726,004 Shares of Biogen Inc. $BIIB](https://longbridge.com/en/news/298275504.md)
- [Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology](https://longbridge.com/en/news/298815400.md)
- [HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir](https://longbridge.com/en/news/298763671.md)
- [Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing](https://longbridge.com/en/news/298400767.md)
- [Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI(R) (lecanemab) for Early Alzheimer's Disease](https://longbridge.com/en/news/298340520.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**